Our results provided evidence of the efficacy of the combined therapy of REMSD and fluoxetine on the treatment of depression, the interaction between the combined therapy and the A1 adenosine receptor, and the ameliorating effects of the combined therapy on depression-induced damage and apoptosis in the hippocampus. The gene discussed is ADORA1; the disease is depressive symptom measurement.